Lantheus (LNTH) Stock Price, News & Analysis

Company Overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Key Stats

• Today's Range: $107.61 to $110.47
• 50-Day Range: $94.91 to $123.19
• 52-Week Range: $50.20 to $126.89
• Volume: 1.16 million shs
• Average Volume: 1.02 million shs
• Market Capitalization: $7.63 billion
• P/E Ratio: 16.80
• Dividend Yield: N/A
• Price Target: $126.00
• Consensus Rating: Moderate Buy

Lantheus Stock Analysis - MarketRank™

Lantheus scored higher than 93% of companies evaluated by MarketBeat, and ranked 77th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Lantheus has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.35%

Earnings Growth

Earnings for Lantheus are expected to grow by 11.35% in the coming year, from $5.99 to $6.67 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lantheus is 16.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.88.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lantheus is 16.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 137.05.

Price to Book Value per Share Ratio

Lantheus has a P/B Ratio of 9.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.13% of the outstanding shares of Lantheus have been sold short.

Short Interest Ratio / Days to Cover

Lantheus has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Lantheus has recently increased by 13.64%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lantheus does not currently pay a dividend.

Dividend Growth

Lantheus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.67

Percentage of Shares Shorted

6.13% of the outstanding shares of Lantheus have been sold short.

Short Interest Ratio / Days to Cover

Lantheus has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Lantheus has recently increased by 13.64%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.01

News Sentiment

Lantheus has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Lantheus this week, compared to 6 articles on an average week.

Search Interest

Only 11 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,922,001.00 in company stock.

Percentage Held by Insiders

Only 1.50% of the stock of Lantheus is held by insiders.

Percentage Held by Institutions

99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LNTH Stock Analysis - Frequently Asked Questions

How have LNTH shares performed this year?

Lantheus' stock was trading at $62.00 on January 1st, 2024. Since then, LNTH shares have increased by 77.5% and is now trading at $110.05.
View the best growth stocks for 2024 here.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its quarterly earnings results on Wednesday, July, 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by $0.07. The firm's revenue was up 22.5% on a year-over-year basis.

When did Lantheus IPO?

Lantheus (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Top institutional investors of Lantheus include Farallon Capital Management LLC (3.29%), Reinhart Partners LLC. (2.12%), Dimensional Fund Advisors LP (1.79%) and Hood River Capital Management LLC (1.55%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Etienne Montagut, Andrea Sabens, Heinz Christoph Maeusli, Gerard Ber, Brian A Markison, Gary J Pruden, Minnie Baylor-Henry and Carol Walker.
View institutional ownership trends.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Lantheus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL) and Exelixis (EXEL).

Company Calendar

• Last Earnings: 7/31/2024
• Today: 9/21/2024
• Next Earnings (Estimated): 11/07/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LNTH
• CUSIP: N/A
• CIK: 1521036
• Web: www.lantheus.com
• Phone: (978) 671-8001
• Fax: 978-671-8860
• Employees: 700
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $126.00
• High Stock Price Target: $175.00
• Low Stock Price Target: $100.00
• Potential Upside/Downside: +14.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $6.55
• Trailing P/E Ratio: 16.80
• Forward P/E Ratio: 18.37
• P/E Growth: N/A
• Net Income: $326.66 million
• Net Margins: 29.80%
• Pretax Margin: 38.53%
• Return on Equity: 48.36%
• Return on Assets: 24.28%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 4.68
• Quick Ratio: 4.41

Sales & Book Value

• Annual Sales: $1.44 billion
• Price / Sales: 5.30
• Cash Flow: $7.28 per share
• Price / Cash Flow: 15.11
• Book Value: $11.91 per share
• Price / Book: 9.24

Miscellaneous

• Outstanding Shares: 69,313,000
• Free Float: 68,273,000
• Market Cap: $7.63 billion
• Optionable: Optionable
• Beta: 0.50